{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T20:46:36Z","timestamp":1791751596515,"version":"4.3.4"},"reference-count":55,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000862","name":"Doris Duke Charitable Foundation","doi-asserted-by":"publisher","award":["2017089"],"award-info":[{"award-number":["2017089"]}],"id":[{"id":"10.13039\/100000862","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000862","name":"Doris Duke Charitable Foundation","doi-asserted-by":"publisher","award":["2017089A"],"award-info":[{"award-number":["2017089A"]}],"id":[{"id":"10.13039\/100000862","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000862","name":"Doris Duke Charitable Foundation","doi-asserted-by":"publisher","award":["2022093"],"award-info":[{"award-number":["2022093"]}],"id":[{"id":"10.13039\/100000862","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.jtct.2026.09.002","type":"journal-article","created":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T16:15:08Z","timestamp":1788538508000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Conditioning Intensity and Outcomes in Pediatric HLA-Identical Transplant for Sickle Cell Disease: Comparison of MAC, RIC, and NMA"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1074-8480","authenticated-orcid":false,"given":"Henna","family":"Butt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8261-5110","authenticated-orcid":false,"given":"Minelys M.","family":"Alicea Marrero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6119-3270","authenticated-orcid":false,"given":"David","family":"Jacobsohn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9156-5960","authenticated-orcid":false,"given":"Kelly Lyons","family":"Snelling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3734-1215","authenticated-orcid":false,"given":"Mamatha","family":"Mandava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Burdett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anqing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2019-0887","authenticated-orcid":false,"given":"Allistair","family":"Abraham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4277-7523","authenticated-orcid":false,"given":"Robert Sheppard","family":"Nickel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtct.2026.09.002_bib0001","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1001484","article-title":"Global burden of sickle cell anaemia in children under five, 2010-2050: modelling based on demographics, excess mortality, and interventions","volume":"10","author":"Piel","year":"2013","journal-title":"PLoS Med"},{"key":"10.1016\/j.jtct.2026.09.002_bib0002","doi-asserted-by":"crossref","first-page":"3775","DOI":"10.1182\/bloodadvances.2022008692","article-title":"Creating an automated contemporaneous cohort in sickle cell anemia to predict survival after disease-modifying therapy","volume":"7","author":"Cronin","year":"2023","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtct.2026.09.002_bib0003","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.15374","article-title":"Estimated life expectancy and income of patients with sickle cell disease compared with those without sickle cell disease","volume":"2","author":"Lubeck","year":"2019","journal-title":"JAMA Network Open"},{"key":"10.1016\/j.jtct.2026.09.002_bib0004","doi-asserted-by":"crossref","first-page":"3668","DOI":"10.1182\/bloodadvances.2021004394C","article-title":"American Society of Hematology 2021 guidelines for sickle cell disease: stem cell transplantation","volume":"5","author":"Kanter","year":"2021","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtct.2026.09.002_bib0005","doi-asserted-by":"crossref","first-page":"594.e1","DOI":"10.1016\/j.jtct.2025.05.004","article-title":"Comparison of regimens used for allogeneic matched related donor hematopoietic cell transplantation for sickle cell disease","volume":"31","author":"Prior","year":"2025","journal-title":"Transplant.Cell.Ther"},{"key":"10.1016\/j.jtct.2026.09.002_bib0006","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1111\/bjh.17311","article-title":"Non-myeloablative human leukocyte antigen-matched related donor transplantation in sickle cell disease: outcomes from three independent centres","volume":"192","author":"Alzahrani","year":"2021","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtct.2026.09.002_bib0007","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1002\/ajh.27295","article-title":"Favorable outcome of non-myeloablative allogeneic transplantation in adult patients with severe sickle cell disease: a single center experience of 200 patients","volume":"99","author":"Damlaj","year":"2024","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jtct.2026.09.002_bib0008","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1002\/ajh.27360","article-title":"Azathioprine\/hydroxyurea preconditioning prior to nonmyeloablative matched sibling donor hematopoietic stem cell transplantation in adults with sickle cell disease: a prospective observational cohort study","volume":"99","author":"Dovern","year":"2024","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jtct.2026.09.002_bib0009","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.jtct.2025.02.021","article-title":"Two nonmyeloablative HLA-matched related donor allogeneic hematopoietic cell transplantation regimens in patients with severe sickle cell disease","volume":"31","author":"Inam","year":"2025","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.jtct.2026.09.002_bib0010","doi-asserted-by":"crossref","first-page":"4160","DOI":"10.1182\/bloodadvances.2025019567","article-title":"Nonmyeloablative HLA-identical sibling transplant for sickle cell disease in children: a multicenter prospective study","volume":"10","author":"Nickel","year":"2026","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtct.2026.09.002_bib0011","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1016\/j.bbmt.2009.07.004","article-title":"Defining the intensity of conditioning regimens: working definitions","volume":"15","author":"Bacigalupo","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2026.09.002_bib0012","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1038\/s41409-024-02251-0","article-title":"Harmonizing definitions for hematopoietic recovery, graft rejection, graft failure, poor graft function, and donor chimerism in allogeneic hematopoietic cell transplantation: a report on behalf of the EBMT, ASTCT, CIBMTR, and APBMT","volume":"59","author":"Sureda","year":"2024","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2026.09.002_bib0013","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1182\/blood-2017-03-772392","article-title":"At least 20% donor myeloid chimerism is necessary to reverse the sickle phenotype after allogeneic HSCT","volume":"130","author":"Fitzhugh","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2026.09.002_bib0014","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1016\/j.bbmt.2017.08.038","article-title":"Relationship between mixed donor-recipient chimerism and disease recurrence after hematopoietic cell transplantation for sickle cell disease","volume":"23","author":"Abraham","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2026.09.002_bib0015","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.3324\/haematol.2019.227561","article-title":"Extensive multilineage analysis in patients with mixed chimerism after allogeneic transplantation for sickle cell disease: insight into hematopoiesis and engraftment thresholds for gene therapy","volume":"105","author":"Magnani","year":"2020","journal-title":"Haematologica"},{"key":"10.1016\/j.jtct.2026.09.002_bib0016","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.bbmt.2014.12.001","article-title":"National Institutes of Health Consensus Development Project on criteria for clinical trials in chronic graft-versus-host disease: I. The 2014 Diagnosis and Staging Working Group report","volume":"21","author":"Jagasia","year":"2015","journal-title":"Biol.Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2026.09.002_bib0017","first-page":"825","article-title":"1994 consensus conference on acute GVHD grading","volume":"15","author":"Przepiorka","year":"1995","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2026.09.002_bib0018","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","article-title":"Research electronic data capture (REDCap): a metadata-driven methodology and workflow process for providing translational research informatics support","volume":"42","author":"Harris","year":"2009","journal-title":"J Biomed Inform"},{"key":"10.1016\/j.jtct.2026.09.002_bib0019","doi-asserted-by":"crossref","first-page":"531.e1","DOI":"10.1016\/j.jtct.2023.05.004","article-title":"Female reproductive health outcomes after hematopoietic cell transplantation for sickle cell disease: is reduced intensity better than myeloablative conditioning?","volume":"29","author":"Meacham","year":"2023","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.jtct.2026.09.002_bib0020","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1038\/s41409-022-01749-9","article-title":"CD34-selected stem cell boost as therapy for late graft rejection following allogeneic transplantation for sickle cell disease","volume":"57","author":"Rangarajan","year":"2022","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2026.09.002_bib0021","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtct.2025.12.275","article-title":"\u0391lpha beta (\u03b1\/\u03b2) T cell depleted second HCT is effective for impending secondary graft failure after reduced intensity and nonmyeloablative MSD HCT in sickle cell disease","volume":"32","author":"Mandava","year":"2026","journal-title":"Transplantation and Cellular Therapy"},{"key":"10.1016\/j.jtct.2026.09.002_bib0022","doi-asserted-by":"crossref","first-page":"E359","DOI":"10.1002\/ajh.26656","article-title":"HLA-matched related donor hematopoietic stem cell transplantation is a suitable treatment in adolescents and adults with sickle cell disease: comparison of myeloablative and non-myeloablative approaches","volume":"97","author":"Dhedin","year":"2022","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jtct.2026.09.002_bib0023","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.bbmt.2015.08.036","article-title":"Nonmyeloablative stem cell transplantation with alemtuzumab\/low-dose irradiation to cure and improve the quality of life of adults with sickle cell disease","volume":"22","author":"Saraf","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2026.09.002_bib0024","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1002\/pbc.24036","article-title":"Health-related quality of life (HRQL) in children with sickle cell disease and thalassemia following hematopoietic stem cell transplant (HSCT)","volume":"59","author":"Kelly","year":"2012","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.jtct.2026.09.002_bib0025","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/1477-7525-11-26","article-title":"Measuring global health-related quality of life in children undergoing hematopoietic stem cell transplant: a longitudinal study","volume":"11","author":"Rodday","year":"2013","journal-title":"Health Qual Life Outcomes"},{"key":"10.1016\/j.jtct.2026.09.002_bib0026","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1016\/j.bbmt.2015.01.010","article-title":"Allogeneic hematopoietic cell transplantation for children with sickle cell disease is beneficial and cost-effective: a single-center analysis","volume":"21","author":"Arnold","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2026.09.002_bib0027","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0229710","article-title":"Improved health care utilization and costs in transplanted versus non-transplanted adults with sickle cell disease","volume":"15","author":"Saraf","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.jtct.2026.09.002_bib0028","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1182\/hematology.2024000550","article-title":"Transfusions, disease-modifying treatments, and curative therapies for sickle cell anemia in Africa: where are we now?","volume":"2024","author":"Odame","year":"2024","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.jtct.2026.09.002_bib0029","doi-asserted-by":"crossref","first-page":"e585","DOI":"10.1016\/S2352-3026(19)30154-1","article-title":"Effect of donor type and conditioning regimen intensity on allogeneic transplantation outcomes in patients with sickle cell disease: a retrospective multicentre, cohort study","volume":"6","author":"Eapen","year":"2019","journal-title":"Lancet Haematol"},{"issue":"4","key":"10.1016\/j.jtct.2026.09.002_bib0030","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1111\/bjh.70381","article-title":"Utility of transplant conditioning intensity score in allogeneic haematopoietic stem cell transplantation for genetic disorders","volume":"208","author":"Kawaguchi","year":"2026","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtct.2026.09.002_bib0031","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1038\/s41409-025-02732-w","article-title":"Transplant conditioning intensity (TCI) score predicts allo-HCT outcomes in patients with myelofibrosis: a study of the Chronic Malignancies Working Party of EBMT","volume":"61","author":"Sobieralski","year":"2026","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2026.09.002_bib0032","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/s41409-023-02139-5","article-title":"Validation of the transplant conditioning intensity (TCI) index for allogeneic hematopoietic cell transplantation","volume":"59","author":"Spyridonidis","year":"2024","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2026.09.002_bib0033","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1038\/s41409-020-0803-y","article-title":"Redefining and measuring transplant conditioning intensity in current era: a study in acute myeloid leukemia patients","volume":"55","author":"Spyridonidis","year":"2020","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2026.09.002_bib0034","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1002\/pbc.25608","article-title":"Survival among children and adults with sickle cell disease in Belgium: BENEFIT from hydroxyurea treatment","volume":"62","author":"L\u00ea","year":"2015","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.jtct.2026.09.002_bib0035","doi-asserted-by":"crossref","first-page":"3447","DOI":"10.1182\/blood-2009-07-233700","article-title":"Improved survival of children and adolescents with sickle cell disease","volume":"115","author":"Quinn","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2026.09.002_bib0036","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1002\/ajh.25799","article-title":"Tricuspid regurgitation velocity and other biomarkers of mortality in children, adolescents and young adults with sickle cell disease in the United States: the PUSH study","volume":"95","author":"Nouraie","year":"2020","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jtct.2026.09.002_bib0037","doi-asserted-by":"crossref","first-page":"S512","DOI":"10.1016\/j.amepre.2009.12.022","article-title":"Population estimates of sickle cell disease in the U.S","volume":"38","author":"Hassell KL","year":"2010","journal-title":"Am J Prevent Med"},{"key":"10.1016\/j.jtct.2026.09.002_bib0038","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1001\/jamapediatrics.2025.2997","article-title":"Mortality rate trends for sickle cell disease and cystic fibrosis in the US","volume":"179","author":"Abraha","year":"2025","journal-title":"JAMA Pediatr"},{"key":"10.1016\/j.jtct.2026.09.002_bib0039","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1007\/s00277-023-05539-1","article-title":"Madrid newborn sickle cell disease cohort: clinical outcomes, stroke prevention and survival","volume":"103","author":"Garc\u00eda-Morin","year":"2024","journal-title":"Ann.Hematol"},{"key":"10.1016\/j.jtct.2026.09.002_bib0040","doi-asserted-by":"crossref","first-page":"905","DOI":"10.3324\/haematol.10937","article-title":"Clinical outcomes in children with sickle cell disease living in England: a neonatal cohort in East London","volume":"92","author":"Telfer","year":"2007","journal-title":"Haematologica"},{"issue":"6","key":"10.1016\/j.jtct.2026.09.002_bib0041","doi-asserted-by":"crossref","first-page":"709.e1","DOI":"10.1016\/j.jtct.2026.02.012","article-title":"Long-term follow-up after mixed donor myeloid chimerism at 1 year post transplantation for sickle cell disease","volume":"32","author":"Guilcher","year":"2026","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.jtct.2026.09.002_bib0042","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1080\/08880018.2021.2013369","article-title":"Post-transplant CD34+ selected stem cell boost as an intervention for declining mixed chimerism following reduced intensity conditioning allogeneic stem cell transplant in children and young adults with sickle cell disease: a case series","volume":"39","author":"Ngwube","year":"2022","journal-title":"Pediatr Hematol Oncol"},{"key":"10.1016\/j.jtct.2026.09.002_bib0043","doi-asserted-by":"crossref","first-page":"47.e1","DOI":"10.1016\/j.jtct.2022.10.012","article-title":"Long-term organ function after HCT for SCD: a report from the sickle cell transplant advocacy and research alliance","volume":"29","author":"Stenger","year":"2023","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.jtct.2026.09.002_bib0044","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1183\/09031936.95.08081269","article-title":"Decreased lung function in one year survivors of allogeneic bone marrow transplantation conditioned with high-dose busulphan and cyclophosphamide","volume":"8","author":"Lund","year":"1995","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jtct.2026.09.002_bib0045","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1016\/j.bbmt.2013.06.005","article-title":"Lung function after allogeneic hematopoietic stem cell transplantation in children: a longitudinal study in a population-based cohort","volume":"19","author":"Uhlving","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2026.09.002_bib0046","doi-asserted-by":"crossref","first-page":"770.e1","DOI":"10.1016\/j.jtct.2022.08.014","article-title":"Comparison of anti-Mullerian hormone levels pre- and post-hematopoietic cell transplantation in pediatric and adolescent females with sickle cell disease","volume":"28","author":"George","year":"2022","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.jtct.2026.09.002_bib0047","doi-asserted-by":"crossref","first-page":"2514","DOI":"10.1182\/blood.2022017960","article-title":"Increased incidence of hematologic malignancies in SCD after HCT in adults with graft failure and mixed chimerism","volume":"140","author":"Lawal","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2026.09.002_bib0048","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1200\/JCO.22.01203","article-title":"Secondary neoplasms after hematopoietic cell transplant for sickle cell disease","volume":"41","author":"Eapen","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2026.09.002_bib0049","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1002\/ajh.24183","article-title":"Successful matched sibling donor marrow transplantation following reduced intensity conditioning in children with hemoglobinopathies","volume":"90","author":"King","year":"2015","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jtct.2026.09.002_bib0050","doi-asserted-by":"crossref","DOI":"10.1111\/ctr.14787","article-title":"The effect of intensity of conditioning regimen on the outcome of HSCT in children with sickle cell disease","volume":"36","author":"Alsultan","year":"2022","journal-title":"Clin Transplant"},{"key":"10.1016\/j.jtct.2026.09.002_bib0051","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1182\/blood.2020005687","article-title":"Risk score to predict event-free survival after hematopoietic cell transplant for sickle cell disease","volume":"136","author":"Brazauskas","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2026.09.002_bib0052","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1038\/s41409-021-01513-5","article-title":"HLA-identical related hematopoietic stem cell transplantation in severe sickle cell disease: age is not a barrier to successful outcome","volume":"57","author":"Alzahrani","year":"2022","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2026.09.002_bib0053","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/s41409-023-02135-9","article-title":"Treosulfan vs busulfan conditioning for allogeneic bmt in children with nonmalignant disease: a randomized phase 2 trial","volume":"59","author":"Sykora","year":"2024","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2026.09.002_bib0054","doi-asserted-by":"crossref","first-page":"91","DOI":"10.3324\/haematol.2018.213207","article-title":"Long-term event-free survival, chimerism and fertility outcomes in 234 patients with sickle-cell anemia younger than 30 years after myeloablative conditioning and matched-sibling transplantation in France","volume":"105","author":"Bernaudin","year":"2020","journal-title":"Haematologica (Roma)"},{"key":"10.1016\/j.jtct.2026.09.002_bib0055","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1182\/blood-2016-10-745711","article-title":"Sickle cell disease: an international survey of results of HLA-identical sibling hematopoietic stem cell transplantation","volume":"129","author":"Gluckman","year":"2017","journal-title":"Blood"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636726007062?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636726007062?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T20:07:51Z","timestamp":1791749271000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636726007062"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":55,"alternative-id":["S2666636726007062"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2026.09.002","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Conditioning Intensity and Outcomes in Pediatric HLA-Identical Transplant for Sickle Cell Disease: Comparison of MAC, RIC, and NMA","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2026.09.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}